Charles W Mcintyre

US Patent:

20220331316, Oct 20, 2022

Filed:

Jul 10, 2020

Appl. No.:

16/926059

Inventors:

- Cambridge MA, US
Dylan ENGLAND - Milford MA, US
Brian Scott FREEZE - Boston MA, US
Zhigen HU - Newton Center MA, US
Steven LANGSTON - Andover MA, US
Charles McINTYRE - Cambridge MA, US
Hirotake MIZUTANI - Arlington MA, US
Koji ONO - Kanagawa, JP
He XU - Needham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/506
C07D 409/14
C07D 409/06
C07D 405/06
C07D 471/04
C07D 495/04
C07D 487/04
C07D 491/052
C07D 513/04
C07D 498/04
C07D 493/04
A61K 31/505
A61K 31/34
C07F 9/535
C07F 9/54
C07F 9/6558
C07F 9/655

Abstract:

Disclosed are chemical entities which are compounds of formula (I):or pharmaceutically acceptable salts thereof; wherein Y, R, R′, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

US Patent:

20200085821, Mar 19, 2020

Filed:

Apr 23, 2019

Appl. No.:

16/391534

Inventors:

- Cambridge MA, US
Dylan ENGLAND - Milford MA, US
Brian Scott FREEZE - Boston MA, US
Zhigen HU - Newton Center MA, US
Steven LANGSTON - Andover MA, US
Charles McINTYRE - Cambridge MA, US
Hirotake MIZUTANI - Arlington MA, US
Koji ONO - Kanagawa, JP
He XU - Needham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/506
C07D 409/14
C07D 409/06
C07D 405/06
C07D 471/04
C07D 495/04
C07D 487/04
C07D 491/052
C07D 513/04
C07D 498/04
C07D 493/04
A61K 31/505
A61K 31/34
C07F 9/535
C07F 9/54
C07F 9/6558
C07F 9/655

Abstract:

Disclosed are chemical entities which are compounds of formula (I):or pharmaceutically acceptable salts thereof; wherein Y, R, R′, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

US Patent:

20180311239, Nov 1, 2018

Filed:

Mar 16, 2018

Appl. No.:

15/923015

Inventors:

- Cambridge MA, US
Dylan ENGLAND - Milford MA, US
Brian Scott FREEZE - Boston MA, US
Zhigen HU - Newton Center MA, US
Steven LANGSTON - Andover MA, US
Charles McINTYRE - Cambridge MA, US
Hirotake MIZUTANI - Arlington MA, US
Koji ONO - Kanagawa, JP
He XU - Needham MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/506
C07D 493/04
C07F 9/535
C07D 513/04
C07D 491/052
C07D 487/04
C07D 495/04
C07D 471/04
C07D 405/06
C07D 409/06
C07D 409/14
A61K 31/505
A61K 31/34
C07F 9/655
C07F 9/6558
C07F 9/54
C07D 498/04

Abstract:

Disclosed are chemical entities which are compounds of formula (I):or pharmaceutically acceptable salts thereof; wherein Y, R, R′, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

US Patent:

20170002032, Jan 5, 2017

Filed:

Jun 30, 2015

Appl. No.:

14/788675

Inventors:

- Cambridge MA, US
Dylan England - Milford MA, US
Scott Freeze - Boston MA, US
Zhigen Hu - Somerville MA, US
Steven Langston - Andover MA, US
Charles McIntyre - Cambridge MA, US
Hirotake Mizutani - Arlington MA, US
Koji Ono - Kanagawa, JP
He Xu - Needham MA, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C07F 9/655
C07D 409/06
C07D 405/06
C07D 471/04
C07D 493/04
C07D 487/04
C07D 491/052
C07D 513/04
C07D 498/04
C07D 409/14
C07D 495/04

Abstract:

Disclosed are chemical entities which are compounds of formula (I):or pharmaceutically acceptable salts thereof; wherein Y, R, R, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

US Patent:

20160355504, Dec 8, 2016

Filed:

Jul 1, 2014

Appl. No.:

14/901809

Inventors:

- Cambridge MA, US
Dylan B. England - Milford MA, US
Zhigen Hu - Somerville MA, US
Mitsuhiro Ito - Fujisawa, Kanagawa, JP
Steven P. Langston - North Andover MA, US
Charles McIntyre - Cambridge MA, US
Hirotake Mizutani - Cambridge MA, US
He Xu - Needham MA, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C07D 403/06
C07D 401/14
C07D 403/14
C07D 405/14
C07D 401/06

Abstract:

Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra′, Rc, Rf, X2, Rd, Rd′, Re, Re′2, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.